Author:
Emberger Jennifer,Hitchcock Matthew M.,Markley J. Daniel
Publisher
Springer Science and Business Media LLC
Reference105 articles.
1. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978;298(10):531–4. https://doi.org/10.1056/NEJM197803092981003.
2. Gerding D, Young V. Clostridium difficile. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier Saunders; 2016.
3. Larson HE, Price AB. Pseudomembranous colitis: presence of clostridial toxin. Lancet. 1977;310(8052):1312–4. https://doi.org/10.1016/s0140-6736(77)90363-4.
4. CDC. Antibiotic resistance threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. https://doi.org/10.15620/cdc:82532.
5. •• Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European society of clinical microbiology and infectious diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22:S63–81. https://doi.org/10.1016/j.cmi.2016.03.010Current ESCMID guidelines for diagnosis of CDI.